The Anti-Apoptotic Activity of BAG3 Is Restricted by Caspases and the Proteasome

Victoria M. Virador, Ben Davidson, Josephine Czechowicz, Alisha Mai, Jareer Kassis, Elise C. Kohn

Molecular Signaling Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America

Abstract

Background: Caspase-mediated cleavage and proteasomal degradation of ubiquitinated proteins are two independent mechanisms for the regulation of protein stability and cellular function. We previously reported BAG3 overexpression protected ubiquitinated clients, such as AKT, from proteasomal degradation and conferred cytoprotection against heat shock. We hypothesized that the BAG3 protein is regulated by proteolysis.

Methodology/Principal Findings: Staurosporine (STS) was used as a tool to test for caspase involvement in BAG3 degradation. MDA435 and HeLa human cancer cell lines exposed to STS underwent apoptosis with a concomitant time and dose-dependent loss of BAG3, suggesting the survival role of BAG3 was subject to STS regulation. zVAD-fmk or caspase 3 and 9 inhibitors provided a strong but incomplete protection of both cells and BAG3 protein. Two putative caspase cleavage sites were tested: KEVD (BAG3E345A/D347A) within the proline-rich center of BAG3 (PXXP) and the C-terminal LEAD site (BAG3E516A/D518A). PXXP deletion mutant and BAG3E345A/D347A or BAG3E516A/D518A respectively slowed or stalled STS-mediated BAG3 loss. BAG3, ubiquitinated under basal growth conditions, underwent augmented ubiquitination upon STS treatment, while there was no increase in ubiquitination of the BAG3E516A/D518A caspase-resistant mutant. Caspase and proteasome inhibition resulted in partial and independent protection of BAG3 whereas inhibitors of both blocked BAG3 degradation. STS-induced apoptosis was increased when BAG3 was silenced, and retention of BAG3 was associated with cytoprotection.

Conclusions/Significance: BAG3 is tightly controlled by selective degradation during STS exposure. Loss of BAG3 under STS injury required sequential caspase cleavage followed by polyubiquitination and proteasomal degradation. The need for dual regulation of BAG3 in apoptosis suggests a key role for BAG3 in cancer cell resistance to apoptosis.

Introduction

Apoptosis following unrecoverable stress results from the activation of proteolytic pathways, which orchestrate the loss of survival proteins. Survival proteins can be degraded directly by activated caspases responding to intrinsic or extrinsic stimuli [1,2] or targeted by the ubiquitin proteasome pathway [3]. Interruption of either or both proteolytic pathways can revert the apoptotic process and result in cytoprotection.

BAG3 (NM_004281) was reported initially as a protein-refolding co-chaperone of the bcl2 binding protein BAG family [4,5] and as upregulated in response to persistent stress of cellular calcium balance dysregulation [6]. It has been shown to diminish stress-induced apoptosis [3,7]. BAG family of proteins contains a conserved BAG domain that binds the ATPase of heat shock protein (Hsp70) [4,8,9]. At least two members of the mammalian BAG family are also involved in cytoprotection, BAG1 [8] and BAG4 [10,11]. This functional redundancy suggests selective targets for the different family members, allowing the family broad potential to protect against varied stresses in different cellular contexts.

We have demonstrated that BAG3, through its interaction with Hsp70, overcame geldanamycin-driven proteasomal protein degradation [7]. Overexpression of BAG3 prevented or reduced destruction of polyubiquitinated Hsp90/Hsp70 client proteins such as cyclin D1, AKT, glycogen synthase kinase 3β, and eIF4G/S6 kinase, and facilitated cell survival [7]. The protective effect of BAG3 was also observed when cells were exposed to heat shock. We also analyzed whether BAG3 provided cytoprotection under intrinsic apoptotic pathway stimulation by staurosporine (STS). By comparison with those other cellular stresses, limited protection was observed with BAG3 overexpression, leading to our current hypothesis that BAG3 is itself lost under selected apoptotic stimuli.

We now report that BAG3 falls victim to STS-induced apoptosis, Loss of BAG3 through RNA silencing augmented STS-mediated apoptosis, whereas, preventing BAG3 proteotoxicity was associated with cytoprotection. We demonstrate a requirement for sequential caspase cleavage followed by ubiquitin...
tination and proteasomal degradation under STS stress. Interruption of both pathways is required to restore BAG3 and overcome the apoptotic drive. The need for this dual and sequential regulation of BAG3 suggests a selective survival role of BAG3 in the cancer cells.

**Results**

STS treatment results in degradation of BAG proteins

STS caused dose- and time-dependent apoptosis in MDA435 human breast cancer cells (Figure 1A). Concomitant with nuclear condensation and cell death due to STS was progressive activation of caspases 3, 7, 8, 9, and 10 (Figure 1B). Caspases 3, 9, and 7 were cleaved earlier and at lower STS doses than caspases 8 or 10, confirming the expected predominant activation of the intrinsic apoptotic pathway. A similar effect was observed in HeLa cells. Apoptosis, demonstrated by the presence of apoptotic bodies, occurred earlier, at 4 and 8 hours (Figure 1C, D and Figure S2B, DMSO control). Cells lacked normal nuclear morphology at later time points, consistent with progressive injury (Fig 1C, arrow head). In BAG3 overexpressing HeLa and MDA435 cells, BAG3 colocalized with active mitochondria early in STS-mediated injury (Figure S1, arrows). Higher concentrations of, or longer exposure to, STS resulted in a generalized uptake of Mito-Tracker into the nucleus, indicating the lack of mitochondrial membrane integrity seen in apoptosis (Figure S1). The dose and time course of activation of caspases 3, 9 and 7 (Figure 1B) paralleled the progressive loss of BAG3 (Figure 1E). Family members BAGs 4, and 6 were similarly lost with STS treatment (Figure 1E, F) as were the commonly used ‘housekeeping proteins’ GAPDH and β-tubulin (Figure S5), while the four isotypes of BAG1, BAG1L, BAG1M, BAG1G, and BAG1S, were unaffected, arguing against a global toxic effect of STS. Both endogenous and forced STS treatment resulted in loss of BAG3 in the B3 cells, whereas loss of BAG3 protein. Stable single cell MDA435 clones overexpressing full length (FL) or deleted (d)PXXP BAG3 [7,12] were exposed to STS. Progressive degradation of BAG3 was observed beginning as early as 4 hr in FL cells (Figure 3A). In contrast, loss of dPXXP-BAG3 was delayed beyond 12 hr. We obtained similar results in HeLa cells with forced expression of EGFP-dPXXP-BAG3 (Figure 3B). This indicates that the effect is neither cell line nor construct-specific, and suggests that the PXXP domain may contain a target site for BAG3 degradation.

The loss of BAG3 upon activation of the intrinsic apoptosis pathway infers BAG3 may be a target of caspases 3, 9 or 7. In silico analysis (ExPASy; http://us.expasy.org/tools/peptidecutter/) did not identify canonical caspase cleavage sites in BAG3. However, two non-canonical putative caspase-cleavage sites were suggested by sequence inspection, 344KEVD and 354KEVD in the PXXP domain and the C-terminal 515LEAD (Figure 3C). KEVD is homologous to the caspase 3 DEVD substrate recognition and cleavage site, and LEAD to the caspase 9 site LEHD [13]. These sites are present in BAG6 (599DEQD) [14]) and BAG4 (521LELD), respectively, but not in BAG1. The BAG3 KEVD/LEAD sites are conserved in upper mammals (Figure 3C, table inset). The importance of these sites is suggested by the conservation of potential caspase 3 (320SEVD) and caspase 9 (320LED) sites in the Drosophila BAG ortholog evi/ starvin (swa, CG32130, FBgn00867) [15].

Alanine mutagenesis was used to neutralize the putative caspase sites, and stable bulk clones of BAG3KAVA, BAG3AAA, and wild type (B3) expressing MDA435 cells were generated. STS treatment resulted in loss of BAG3 in the B3 cells, whereas loss was limited in BAG3KAVA cells and minimal in BAG3AAA (Figure 3D). These data argue that 344KEVD and 515LEAD are not identify canonical caspase cleavage sites in BAG3. However, selective and pan-caspase inhibition. The broad caspase inhibitor Z-Val-Ala-Asp(OMe) fluoromethyl ketone (zVAD) abrogated caspase activation and loss of BAG3 in the presence of STS (Figure 3E). Selective inhibition of caspases 3, 10, or both partially prevented BAG3 proteolysis consistent with caspase3 involvement. Notice that the antibody against caspase 3 is selective to the cleaved forms and detects two active cleaved species with apparent mobility of 19 and 14 kDa; the antibody to caspase 10 detects only the uncleaved, total caspase 10, which disappears upon cleavage stimulated by STS treatment. Caspase 10 activation is only partly protected by individual caspase inhibitors and maximally protected by zVAD. Taken together, these results indicate a caspase-dependent cleavage of BAG3 but suggest that additional steps may be needed for complete BAG3 loss.

**BAG3 is a caspase substrate**

BAG3 3, 4, and 6, all susceptible to STS-mediated degradation, have structural similarities not present in BAG1. Conversely, the STS-resistant BAG1 lacks domains present in BAGs 3, 4 and 6, as the proline rich region PXXP. We examined whether deletion of the PXXP domain in BAG3 would affect STS-induced loss of BAG3 protein. Stable single cell MDA435 clones overexpressing full length (FL) or deleted (d)PXXP BAG3 [7,12] were exposed to STS. Progressive degradation of BAG3 was observed beginning as early as 4 hr in FL cells (Figure 3A). In contrast, loss of dPXXP-BAG3 was delayed beyond 12 hr. We obtained similar results in HeLa cells with forced expression of EGFP-dPXXP-BAG3 (Figure 3B). This indicates that the effect is neither cell line nor construct-specific, and suggests that the PXXP domain may contain a target site for BAG3 degradation.

The loss of BAG3 upon activation of the intrinsic apoptosis pathway infers BAG3 may be a target of caspases 3, 9 or 7. In silico analysis (ExPASy; http://us.expasy.org/tools/peptidecutter/) did not identify canonical caspase cleavage sites in BAG3. However, two non-canonical putative caspase-cleavage sites were suggested by sequence inspection, 344KEVD and 354KEVD in the PXXP domain and the C-terminal 515LEAD (Figure 3C). KEVD is homologous to the caspase 3 DEVD substrate recognition and cleavage site, and LEAD to the caspase 9 site LEHD [13]. These sites are present in BAG6 (599DEQD) [14]) and BAG4 (521LELD), respectively, but not in BAG1. The BAG3 KEVD/LEAD sites are conserved in upper mammals (Figure 3C, table inset). The importance of these sites is suggested by the conservation of potential caspase 3 (320SEVD) and caspase 9 (320LED) sites in the Drosophila BAG ortholog evi/ starvin (swa, CG32130, FBgn00867) [15].

Alanine mutagenesis was used to neutralize the putative caspase sites, and stable bulk clones of BAG3KAVA, BAG3AAA, and wild type (B3) expressing MDA435 cells were generated. STS treatment resulted in loss of BAG3 in the B3 cells, whereas loss was limited in BAG3KAVA cells and minimal in BAG3AAA (Figure 3D). These data argue that 344KEVD and 515LEAD are not identify canonical caspase cleavage sites in BAG3. However, selective and pan-caspase inhibition. The broad caspase inhibitor Z-Val-Ala-Asp(OMe) fluoromethyl ketone (zVAD) abrogated caspase activation and loss of BAG3 in the presence of STS (Figure 3E). Selective inhibition of caspases 3, 10, or both partially prevented BAG3 proteolysis consistent with caspase3 involvement. Notice that the antibody against caspase 3 is selective to the cleaved forms and detects two active cleaved species with apparent mobility of 19 and 14 kDa; the antibody to caspase 10 detects only the uncleaved, total caspase 10, which disappears upon cleavage stimulated by STS treatment. Caspase 10 activation is only partly protected by individual caspase inhibitors and maximally protected by zVAD. Taken together, these results indicate a caspase-dependent cleavage of BAG3 but suggest that additional steps may be needed for complete BAG3 loss.

**BAG3 is ubiquitinated and degraded by the proteasome**

Proteasomal degradation is a major protein regulatory mechanism [16,17]. Chemical inhibitors of the 20S subunit of the proteasome, such as lactacystin and MG-132, prevent degradation of polyubiquitinated proteins [18]. Neither mutation of the KEVD caspase-recognition site, nor pharmacological inhibition of selected caspases afforded complete protection of BAG3 in the face of intrinsic apoptosis pathway activation, suggesting complementary proteolytic mechanisms. Addition of MG-132 to STS resulted in near complete BAG3 retention (Figure 4A). MG-132 pretreatment in the absence of STS caused accumulation of poly-ubiquitinated
BAG3, indicating that some BAG3 ubiquitination occurs basally (Figure 4B, lane 1). Augmented ubiquitination of BAG3 was demonstrated with the combination of STS and MG-132 arguing that BAG3 is targeted to the proteasome under STS stress (Figure 4B, lane 4 v. lane 1). We next investigated the complementarity of pharmacological inhibition of both caspases and the proteasome on BAG3 rescue. Some protection of BAG3 was seen with proteasome inhibition alone (Figure 4C), while there was no BAG3 degradation when zVAD and MG-132 were used in combination. A plot of these data demonstrates progressive loss of BAG3 in the presence of MG-132. This is attenuated with the combination of zVAD and MG-132. These results were

---

**Figure 1. STS induced apoptosis and degradation of BAG3.**

A. STS induces cellular injury in a dose and time-dependent fashion. DAPI-stained STS-treated MDA435 cells show chromatin condensation consistent with apoptotic injury. Apoptotic bodies were observed with 2 and 4 μM STS at 4 hr (arrows) and there was a net loss of cells at 16 hrs. B. STS-mediated degradation of BAG3 occurs concomitant to activation of caspases 3, 7 and 9. Cleavage of caspases 3 and 9 were observed as early as 4 hrs into STS treatment. In comparison activation of caspases 8 and 10 was delayed, occurring after BAG protein loss was initiated. C, D. STS induces apoptosis in HeLa cells. Apoptotic bodies were observed in DAPI stained cells. Data points are the mean and SEM of five independent fields (n = 2). E, F. BAGs 3, 4, and 6 are lost progressively with STS exposure. Floating and adherent MDA435 cells were collected, lysed, and subjected to immunoblot. BAGs 3 and 4 (E), and 6 (F) were lost with STS exposures of 3–16 hrs. No reduction in the p50, p46, p34, or p29 BAG1 isoforms was observed (E). G. STS-mediated BAG3 degradation is neither cell line nor construct-specific. EGFP-BAG3 or EGFP-C1 empty vector were stably expressed in HeLa cells. Cells were exposed to 2 μM STS and both endogenous BAG3 and EGFP-BAG3 fusion proteins were lost over time, as early as 6 h.

doi:10.1371/journal.pone.0005136.g001
Recapitulated when lactacystin was used as a proteasomal inhibitor. Disappearance of BAG3 signal caused by STS was prevented by pre-treatment with lactacystin (Figure S3A). The combination zVAD and lactacystin prevented loss of BAG3 in FL and dPXXP cells, while minimally affecting the already resistant dPXXP form (Figure S3B). Taken together these data suggest that both caspase cleavage and proteasomal degradation are required for the degradation of BAG3 in STS-driven apoptosis and that the role of caspase cleavage may be primary.

Noncleavable BAG3 is protected from STS-induced ubiquitination and degradation

Our data implicate both caspase cleavage and ubiquitination in the regulation of BAG3 quantity. The suggestion that caspase cleavage has a primary role in BAG3 degradation led us to propose that the process is sequential, with one mechanism as a prerequisite for the other. We thus tested whether caspase site mutants, BAG3KAVA and BAG3LAAA, are prone to ubiquitination. BAG3LAAA was minimally ubiquitinated. Ubiquitination changed little over the time course of STS exposure, remaining commensurable with that seen during basal turnover of BAG3 (Figure 5). Progressive ubiquitination of BAG3KAVA was observed, maximal at 20 hr, as more of the BAG3 substrate became available due to impaired caspase cleavage. These data demonstrate that caspase cleavage of BAG3 is necessary for stimulated ubiquitination and degradation.

Noncleavable BAG3 protects cells from STS-induced apoptosis

Our data showing silencing of BAG3 increased susceptibility to STS-mediated apoptosis led us to ask if the caspase-resistant mutants conferred cytotoxicity. Apoptotic bodies in DAPI-stained STS-treated cells were counted in wild type MDA435 and MDA_FL overexpressors. A progressive reduction in apoptotic bodies was observed upon STS treatment with added zVAD, or zVAD plus MG-132, supporting a role for the loss of BAG3 augmenting STS cell injury (Figure 6A,B). Similarly, dPXXP cells lacking the KEVD sequence underwent significantly less apoptosis than wild type cells or FL-BAG3 (Figure 6C). This decrease in apoptosis is also demonstrated by delayed and reduced PARP cleavage and total PARP loss under the same conditions (Figure 6D). PARP cleavage was reduced and delayed in BAG3KAVA and total PARP was only minimally reduced in BAG3LAAA cells, consistent with cellular protection. The intermediate resistance to STS apoptosis of BAG3KAVA is also demonstrated by reduced caspase 3 activation, which decreased progressively from B3 to BAG3KAVA to BAG3LAAA cells (Figure 6F). Collectively these results indicate dose-dependent cytoprotection from apoptosis is afforded by BAG3. When over expressed BAG3 delays, but does not abrogate, cellular commitment to apoptosis. Prevention of BAG3 degradation through blockade of caspase cleavage and subsequent ubiquitination results in cellular protection from STS-mediated apoptosis.

Discussion

Survival is controlled by the balance of information within the cell in response to gene expression, protein translation, and protein and message stability as a function of the cellular microenvironment. Cellular and environmental stresses can lead to apoptosis. The two most common mechanisms for protein loss in apoptosis are direct caspase cleavage, and proteasomal degradation of ubiquitinated proteins [3,19,20]. The prosurvival protein, BAG3, protects cells from apoptosis caused by heat [5,7]. We hypothetized that decreased cellular survival in response to STS was due to destruction of BAG3 protein through STS-stimulated caspase activation. This was confirmed through demonstration that BAG3 was lost in response to STS, in a time- and dose-dependent fashion, temporally correlated with activation of caspases 3, 9, and 7. The involvement of caspases in BAG3 degradation was established by protection of BAG3 in the presence of the pan-caspase inhibitor zVAD and by mutagenesis of putative caspase recognition sites. However, BAG3 was not completely protected by individual caspase inhibitors or by mutation of the caspase 3 site KEVD (BAG3KAVA). This led to the conclusion that other proteolytic events were required. Inclusion of proteasome inhibitors provided partial protection of BAG3 protein that was complementary with zVAD. BAG3 was polyubiquitinated in MDA435 cells in the absence of stress, consistent with proteasome involvement in basal BAG3 turnover; progressive ubiquitination and subsequent BAG3 loss was observed with STS. Little or no ubiquitination of caspase-resistant BAG3LAAA was observed, while increased ubiquitination was seen in BAG3KAVA as expected because of its partial protection from caspase cleavage and loss. Since absence of BAG3 cleavage precluded ubiquitination, these data argue a requirement for sequential caspase cleavage followed by ubiquitination. Protection of BAG3 translated into cellular protection against STS-induced apoptosis. In forced BAG3 expression experiments, cytoprotection correlated with the molecular construct most resistant to degradation. In contrast, silencing BAG3 augmented STS-mediated apoptosis. Together these data confirm that BAG3 functions as a pro-survival protein, the presence of which is regulated by caspase cleavage followed by ubiquitination and proteasomal degradation. It further suggests that impaired BAG3 degradation is central in the protection of cancer cells against intrinsin apoptotic pathway stress.

Many important signaling proteins are controlled by polyubiquitination, including p33 [21], p21^WAF [22], c-Jun [23], and c-fos [24]. These proteins are targets for polyubiquitination and chaperoned to the proteosome by heat shock proteins [25,26] for subsequent de-ubiquitination and cleavage [3,7]. Other proteins, such as APAF-1 [27] or MDM2 [28], are regulated by caspase cleavage. Relatively few proteins, such as the small heat shock co-chaperone p23 [17], are regulated by both caspases and the proteosome. Many other important survival proteins are regulated by either caspases or the proteosome (but not both) in different cellular contexts. Examples among this group are AKT [1,7], BcI2 and BcIm [2]. However, it remains unclear whether regulation of
Figure 3. **BAG3 is a direct caspase substrate.** A. Deletion of the BAG3 PXXP domain delays loss of BAG3. Clonal FL-BAG3 and (d)PXXP-BAG3 MDA435 cells were treated with 2 μM STS as indicated. Cells were lysed and subjected to immunoanalysis with anti-BAG3. Delayed loss of dPXXP-BAG3, which contains putative caspase recognition sequence KEVD, is demonstrated compared with wild type protein. The delayed loss of dPXXP-BAG3 is confirmed in HeLa cells engineered to stably express EGFP-dPXXP-BAG3 by anti-EGFP (B). C. Location and alignment of putative caspase cleavage sites in BAGs 3, 4 and 6. KEVD (caspase 3 recognition site in the PXXP domain; arrow) and LEAD (caspase 9 recognition site; arrow head). Similar sites, represented to approximate scale, are found in BAGs 4 (421LELD) and 6 (998DEQD) [14,37], but not in BAG1. These putative caspase cleavage sites are conserved in mammalian BAG proteins and in a Drosophila homolog (inset table). D. Mutation of either putative caspase cleavage site reduced loss of BAG3. Alanine mutagenesis of 344KEVD or 515LEAD was followed by stable transfection and expression. BAG3 was markedly decreased in B3 cells in response to 2 μM STS at the indicated times. BAG3KAVA cells retained much of their BAG3 protein up to 18 hr STS exposure and little or no BAG3 was lost in BAG3LAAA cells. E. Inhibition of caspases resulted in incomplete loss of BAG3. One hour pretreatment with 85 μM zVAD, followed by 2 μM STS up to 20 h, protected BAG3 as did the combination of caspase3 and 10 inhibitors; specific inhibitors concentrations were 40 μM for caspases 3 and 9, and 50 μM for caspase 10. The antibody against cleaved caspase 3 is selective to the cleaved forms and detects two active cleaved species with apparent mobility of 19 and 14 kDa. This latter species is described a further cleavage product. The antibody to caspase 10 detects only the uncleaved, total caspase 10. Arrows indicate target protein bands.

doi:10.1371/journal.pone.0005136.g003
these proteins requires involvement of both the caspase and proteasome pathways as is shown herein for regulation of BAG3. The evidence for caspase cleavage of BAG3 is strong, even in the absence of canonical caspase binding and cleavage sites. Two putative caspase recognition and cleavage sites, each containing the ExD sequence [13,29–31], were identified in silico and then confirmed functionally in human BAG3. These sites were relatively well conserved in mammalian BAG3 and in BAGs 4 and 6, the latter having been reported to be functional [14]. The caspase 3-like motif K/RexD and the caspase 9-like LexD are conserved in BAG3 in higher mammals. The caspase 3 motif is also present in the Drosophila Evil/Starvin [15] as SEVD, although the caspase 9-like peptide LKLD, more important to hBAG3 stability per our studies, may not be functional.

Drosophila Starvin was initially identified by Coulson and colleagues in a search for binding proteins to Polycomblike protein [15] but when further analyzed was found to have similarity to human BAGs 3, 4 and 5. We had reported the same Drosophila protein, identified as Evil (Frueauf et al. (2005) Cloning of evil: Characterization of Drosophila melanogaster BAG-family homologues. AACR Meeting Abstracts 2005: 825-a), as the Drosophila BAG3/4 homolog and demonstrated conservation of Hsp70 binding. Further, we have shown that when expressed ectopically in human cancer cells, Evil/Starvin is also a stress response survival protein (Frueauf, Virador, Kohn, manuscript in preparation). Starvin functions as a stress response and survival protein in flies with a phenotype that has similarity to two different BAG3 knockout mice [32,33]. These findings confirm the conserved importance of BAG3/Evil/Starvin protection for selected cell survival.

We and others showed that BAG3 overexpression provided cytoprotection from a variety of stresses. Overexpression of BAG3, but not BAG domain deletion mutants, protected from heat shock [7]. BAG3 overexpression, alone or in combination with ectopic

**Figure 4. Sequential inhibition of caspases and proteasome provides collaborative protection of BAG3.**

A. Proteasome inhibition provides dose-dependent partial protection of BAG3. FL-BAG3 cells were pretreated with 20 μM MG-132 for 1 or 4 hrs prior to exposure to 2 μM STS. Inhibition of proteasomal degradation by pretreatment with MG-132 prior to STS exposure reduced BAG3 degradation. B. BAG3 is ubiquitinated in response to STS treatment. FL-BAG3 cells were treated with 2 μM STS alone or following 4 hr preincubation with 20 μM MG-132. Lysates were immunoprecipitated with anti-BAG3 and the immunoblots were probed for ubiquitin. BAG3 was ubiquitinated and degraded in the absence of proteasome inhibition. C. STS-induced loss of BAG3 is minimized by the combination of caspase and proteasomal inhibition. FL-BAG3 cells were preincubated with 0.05% DMSO vehicle or 20 μM MG-132 for 4 hours with or without 1 additional hour of zVAD preincubation (85 μM). Treatments were followed by a total STS exposure of up to 20 hrs. A progressive retention of BAG3 was seen with inclusion of each inhibitor. Relative levels of BAG3, determined using ImageJ, are indicated below the respective blots and plotted as percent remaining BAG3 with increasing STS time. doi:10.1371/journal.pone.0005136.g004
expression of bcl2, overcame bax-mediated apoptosis [5]. The bax/bcl2 apoptotic machinery is linked to the intrinsic apoptotic pathway and the overexpression of BAG3 in those experiments may have been sufficient to overcome that degree of caspase activation. This is similar to our findings that overexpression of BAG3 yields some reduction in apoptotic bodies in response to STS, even more prominently in the practically protected dPXXP BAG3 (Figure 6). Loss of BAG3 by silencing also augmented cell death in response to STS. This same increased apoptosis was reported when BAG3 was silenced in acute and chronic lymphocytic leukemia cells [34,35]. Thus, protection of BAG3 may have been sufficient to overcome that degree of caspase pathway and the overexpression of BAG3 in those experiments unless otherwise indicated.

Materials and Methods

Cell culture and transfectants

The MDA435 human breast cancer cell line and stable transfectant single cell clones containing full length BAG3 (FL) and PXXP domain-deleted BAG3 (d)PXXP-BAG3 have been reported [7,12]. These constructs were subcloned into pEGFP-C1 (BD Biosciences, Palo Alto, CA) for transfection into HeLa cells. EGFP transfectants were sorted by FACS to enrich for GFP-positive cells. Site-directed mutagenesis was used to generate BAG3E345A/D347A (BAG3KAVA) and BAG3E516A/D518A (BAG3LAAA; Bio S&T Inc, Montreal, CAN). Unless otherwise indicated all transfectants were selected in bulk. Cells were cultured in maintenance concentrations of G418 until one passage prior to experiments. All experiments were performed in triplicate.

Cell lysates, immunoblotting and immunoprecipitation

All experiments were done with subconfluent cells. STS or 0.05% DMSO vehicle control were added for the times and concentrations noted. Floating and attached cells were pooled for all analyses. Cell lysis and immunoblotting were performed as reported [7]. Iodoacetamide 10 mM was added to the modified RIPA lysis buffer for studies of ubiquitination [7]. Urea 4 M was added to the sample buffer for PARP immunoanalysis and samples were heated at 95°C for 7 min prior to loading. Anti-ubiquitin (Ub) and -PARP antibodies were from StressGen (Victoria BC, Canada); antibodies against caspase 10, cleaved (cl) caspase-3 (Asp175), cl caspase-7 (Asp190), cl caspase-8 (Asp304), and cl caspase-9 (Asp330) were from Cell Signaling (Beverly, MA). Antibodies to GAPDH and β-tubulin were from Abcam (Cambridge, MA). Antibodies to Bag1 and Bag4 were from Santa Cruz Biotechnology, Inc (Santa Cruz, CA); anti-peptide Bag3 and Bag6 antibodies have been reported [7,36]. Specific caspase inhibitors were from Calbiochem (San Diego, CA), all other chemicals from Sigma (St. Louis, MO).

Immunofluorescence microscopy

Cells were plated on uncoated glass coverslips and allowed to secrete and adhere to their own extracellular matrix for 2–3 days. After treatment, cells were fixed in 4% formaldehyde, rinsed in PBS and blocked for 1 hr in PBS containing 3% BSA. Cells were stained with antibodies to BAG3 (1:500 dilution) and counter-stained with DAPI (Vector laboratories, Burlingame, CA). Where indicated, cells were loaded with MitoTracker Red CMXRos (Invitrogen, CA), following manufacturer’s recommendations. Fluorescence was examined with a Zeiss LSM 510 Confocal Microscope (Carl Zeiss Inc, Thornwood, NY, USA) using a 1.3 NA Plan Neofluar objective. To assess apoptosis the number of cells containing apoptotic bodies was expressed as a percent of the total cells visualized.

Flow cytometry

Intracellular protein expression was assessed according to manufacturer’s protocol (Cell Signaling, Inc). Permeabilized cells were incubated with antibodies against cl caspase-3 1:200 or BAG3 (1:500 dilution) and counter-stained with DAPI (Vector laboratories, Burlingame, CA). Where indicated, cells were loaded with MitoTracker Red CMXRos (Invitrogen, CA), following manufacturer’s recommendations. Fluorescence was examined with a FACS Calibur flow cytometer (BD Biosciences, San Jose, CA). Data were analyzed using FlowJo (TreeStar Inc, Palo Alto, CA).

Gene silencing

BAG3 and control (non-silencing) siRNA were purchased from Qiagen, Inc. (Valencia, CA); siBag3 40 nM or molar equivalent non-silencing siRNA were introduced to cells in siLentFectTM lipid reagent (Bio-Rad, Hercules, CA) as described [12]. Reagents were added to the cells after up to 96-hour siRNA incubation and counter-stained with cl PARP (Asp214) added according to manufacturer’s protocol (Cell Signaling, Inc). Permeabilized cells were incubated with antibodies against cl caspase-3 1:200 or BAG3 (1:500 dilution) and counter-stained with DAPI (Vector laboratories, Burlingame, CA). Analysis was carried out on a FACS Calibur flow cytometer (BD Biosciences, San Jose, CA). Data were analyzed using FlowJo (TreeStar Inc, Palo Alto, CA).

Statistical analysis

Numerical values are expressed as mean±SEM of replicate experiments unless otherwise indicated. Comparisons between two
Figure 6. Absence of caspase cleavage of BAG3 confers cellular protection against STS-mediated apoptosis. A, B. STS-induced apoptosis was reduced with caspase and proteasome inhibition. Cells were pretreated with MG-132 for 4 hrs and treated with 2 μM STS and 85 μM zVAD-fmk for an additional 8 hrs. Wild type MDA435 (A) and FL-BAG3 overexpressors were fixed and stained with DAPI and apoptotic bodies scored from 3–5 independent fields; data represent mean and SEM (n = 2). C. Apoptosis is delayed in dPXXP-BAG3 lacking KEVD. At 8 hours of STS exposure, reduction in apoptotic bodies is seen in FL-BAG3 overexpressing cells and in dPXXP-BAG3 cells; 11–14 random fields were scored, data represent mean and SEM. D. PARP cleavage and loss of total PARP is reduced in dPXXP-BAG3 cells. STS exposure resulted in reduced PARP cleavage in
FL cells compared to Neo controls, and both reduced and delayed PARP cleavage in DPXXP-BAG3 cells. E. F. Reduced apoptosis occurs in caspase-resistant BAG3 transfectants. FL-BAG3 wild type, BAG3++/+ and BAG3+++ were treated with 2 μM STS or 0.05% DMSO vehicle control as shown. Delayed and reduced PARP cleavage is demonstrated in cells overexpressing KEVD and LEAD BAG3 mutants. Cleaved caspase-3, an earlier apoptotic event, was measured by flow cytometry after 6 h STS treatment. As with PARP cleavage, BAG3+++ had the least cleavage of caspase 3, the right panel shows a representative histogram; data represent mean and SEM (n = 2).
doi:10.1371/journal.pone.0005136.g006

Supporting Information

Figure S1 A fraction of BAG3 co-localizes with mitochondria in early STS-mediated stress. BAG3 stained cells (green) loaded with Mito Tracker (red) and counterstained with DAPI (blue). Arrows show colocalization in yellow. At higher STS doses, there is loss of the BAG3 green signal and a generalized uptake of Mito Tracker in cell nuclei (arrow head) indicating loss of both nuclear and mitochondrial membrane integrity.

Figure S2 BAG3 is transiently induced in early STS-mediated stress. A. Flow cytometry of MDA435 cells stained for BAG3 (secondary Alexa 666 anti Rabbit) and subject to increasing STS doses. B. MDA435 cells stained for BAG3 after 4 h STS exposure (secondary Alexa 594 anti Rabbit).

Figure S3 Inhibition of caspases and proteasome provides collaborative protection of BAG3. A. Proteasome inhibition with lactacystin (1 μM, 4 hr preincubation) in MDA-435 cells overexpressing BAG3 or BAG3-3PXXP provides partial protection of BAG3. B. Lactacystin in combination with zVAD provides near full protection of BAG3, similar to MG-132.

Figure S4 Disappearance of the BAG3 signal by siRNA. MDA435-Neo cells were exposed to 200 nM BAG3 siRNA or scramble control for 72 hours followed by addition of vehicle control or 2μM STS for additional 6 hrs. Immunoblot demonstrates silencing of BAG3.

Figure S5 Commonly used ‘housekeeping proteins’ are degraded by STS in HeLa and MDA 435 cells. A. HeLa cells overexpressing BAG3. BAG3 signal disappears with increasing time of exposure to 2 μM STS. GAPDH (re-blot) likewise disappears with STS exposure. B. MDA435 cells. BAG3 signal disappears with STS and is protected by addition of MG-132 or MG-132 and zVAD in combination. The signal for β-tubulin (re-blot) diminishes with STS exposure.

Acknowledgments

The authors thank Dr. D. Gius for critical discussions and helpful advice. We also thank J. Zakhari, B. Taylor and S. Garfield for expert technical assistance.

Author Contributions

Conceived and designed the experiments: VV ECK. Performed the experiments: VV BD JC AM JK. Analyzed the data: VV BD JC JK ECK. Wrote the paper: VV ECK.

References

1. Widmann C, Gibson S, Johnson GL (1998) Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals. J Biol Chem 273: 7141–7147.
2. Karran L, Dyer MJ (2001) Proteolytic cleavage of molecules involved in cell death or survival pathways: a role in the control of apoptosis? Crit Rev Eukaryot Gene Expr 11: 269–277.
3. Asher G, Reuven N, Shaul Y (2006) 20S proteasomes and protein degradation “by default”. Bioessays 28: 844–849.
4. Takayama S, Xie Z, Reed JC (1999) An evolutionarily conserved family of Hsp70/Hsc70 molecular chaperone regulators. J Biol Chem 274: 781–786.
5. Lee JH, Takahashi T, Yasuhara N, Inazawa J, Kamada S, et al. (1999) Bc, a Bc-2-binding protein that synergizes with Bc-2 in preventing cell death. Oncogene 18: 6183–6190.
6. Doong H, Price J, Kim YS, Gasbarre C, Probst J, et al. (2000) CAIR-1/BAG-3 forms an EGF-regulated ternary complex with phospholipase C-gamma and Hsp70/Hsc70. Oncogene 19: 4383–4395.
7. Doong H, Rizzo K, Fang S, Keul C, Gao B, Lee SM, Fang D (2006) The tyrosine kinase c-Abl protects c-Jun from ubiquitination-mediated degradation in T cells. J Biol Chem 281: 29711–29718.
8. Takayama S, Xie Z, Reed JC (1999) An evolutionarily conserved family of Hsp70/Hsc70 molecular chaperone regulators. J Biol Chem 274: 781–786.
9. Lipton SA, Johnson GL (1997) Caspase-dependent cleavage of molecules involved in cell death. Cell 90: 481–486.
10. Oyadomari S, Yamakawa T, Yamaguchi Y, Nagata S (2002) A novel Bc-2-binding protein that synergizes with Bc-2 in preventing cell death. Oncogene 21: 6727–6739.
11. Liu W, Zhou X, Zeng Y, Zhang Z, Yin X, et al. (2003) The BAG-3 protein has antiapoptotic activity. J Biol Chem 278: 38190–38199.
12. Kassis JN, Guancial EA, Doong H, Virador V, Kohn EC (2006) CAIR-1/BAG-3: A Bc-2-binding protein that synergizes with Bc-2 in preventing cell death. J Biol Chem 279: 29711–29718.
13. Earnshaw WC, Martins LM, Kaufmann SH (1999) Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68: 383–424.
14. Wu YH, Shah SF, Lin JY (2004) Ricin triggers apoptotic morphological changes through caspase-3 cleavage of BAT3. J Biol Chem 279: 19264–19275.
15. Coulson M, Robert S, Saint R (2005) Drosophila starin Encodes a Tissue-Specific BAG-Domain Protein Required for Larval Food Uptake. Genetics 171: 1799–1812.
16. Ciechanover A (2005) Proteolytic from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 6: 78–87.
17. Mollerup J, Berchtold MW (2005) The co-chaperone p23 is degraded by caspases and the proteasome during apoptosis. FEBS Lett 579: 417–422.
18. Kisselev AF, Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8: 739–758.
19. Nicholson DW, Thornberry NA (2003) Apoptosis. Life and death decisions. Science 299: 214–215.
20. Bendjennat M, Boulaire J, Jascur T, Brickner H, Barbier V, et al. (2003) UV irradiation triggers ubiquitin-dependent degradation of p21(WAF1) to promote DNA repair. Cell 114: 599–610.
21. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296–299.
22. Basbous J, Chalbos D, Hipskind R, Jariel-Encontre I, Piechaczyk M (2007) Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer. Mol Cell Biol 27: 3939–3950.
23. Evd Mikulas SM, 2001) Stressed to death: regulation of apoptotic signaling pathways by the heat shock proteins. Sci STKE 2001: RE1.
24. Didecot L, Schmitt E, Brunet M, Maignent L, Parcellier A, et al. (2006) Heat shock proteins: endogenous modulators of apoptotic cell death. Handb Exp Pharmacol pp 171–190.
25. Lauber K, Appel HA, Schlort SF, Gregor M, Schulze-Osthoff K, et al. (2001) The adapter protein apoptotic protease-activating factor-1 (Apaf-1) is proteolytically processed during apoptosis. J Biol Chem 276: 29772–29781.
28. Pochampally R, Fodera B, Chen L, Shao W, Levine EA, et al. (1998) A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells. Oncogene 17: 2629–2636.

29. Thornberry NA, Rando TA, Peterson EP, Rasper DM, Timkey T, et al. (1997) A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem 272: 17907–17911.

30. Han Z, Pantazis P, Lange TS, Wyche JH, Hendrickson EA (2000) The staurosporine analog, Ro-31-8220, induces apoptosis independently of its ability to inhibit protein kinase C. Cell Death Differ 7: 521–530.

31. Fischer U, Janicke RU, Schulze-Osthoff K (2003) Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 10: 76–100.

32. Homma S, Iwasaki M, Shelton GJ, Enyedi E, Reed JC, et al. (2006) BAG3 deficiency results in fulminant myopathy and early lethality. Am J Pathol 169: 761–773.

33. Youn DY, Lee DH, Lim MH, Yoon JS, Lim JH, et al. (2008) Bix deficiency results in early lethality with metabolic deterioration and involution of the spleen and thymus. Am J Physiol Endocrinol Metab.

34. Bonelli P, Petrella A, Rosati A, Romano MF, Lerose R, et al. (2004) BAG3 protein regulates stress-induced apoptosis in normal and neoplastic leukocytes. Leukemia 18: 358–360.

35. Romano MF, Festa M, Pagliuca G, Lerose R, Bisogni R, et al. (2003) BAG3 protein controls B-chronic lymphocytic leukaemia cell apoptosis. Cell Death Differ 10: 383–385.

36. Annunziata CM, Kleinberg L, Davidson B, Berner A, Gian D, et al. (2007) BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer. Clin Cancer Res 13: 6585–6592.

37. Thress K, Song J, Morimoto RI, Kornbluth S (2001) Reversible inhibition of Hsp70 chaperone function by Scythe and Reaper. Embo J 20: 1033–1041.